An influential, independent panel unanimously voted that aducanumab (Aduhelm) offers no benefit for patients with Alzheimer’s disease (AD), adding to growing opposition from medical experts to the US Food and Drug Administration’s (FDA’s) approval of this controversial drug. The Institute for Clinical and Economic Review (ICER) asked one of its expert panels, the California Technology Assessment Forum, to consider the available...
Tag: <span>Aducanumab</span>
Post
No Net Benefit of Aducanumab for Alzheimer’s Disease, Expert Panel Rules
Kerry Dooley Young July 16, 2021 An influential, independent panel unanimously voted that aducanumab (Aduhelm) offers no benefit for patients with Alzheimer’s disease (AD), adding to growing opposition from medical experts to the US Food and Drug Administration’s (FDA’s) approval of this controversial drug. The Institute for Clinical and Economic Review (ICER) asked one of its expert panels, the California Technology Assessment Forum,...